Interactive effects of asparagine and aspartate homeostasis with sex and age for the risk of type 2 diabetes risk

Hui-Huan Luo  
Tianjin Medical University

Xiao-Fei Feng  
Tianjin Medical University

Xi-Lin Yang  
Tianjin Medical University

Rui-Qin Hou  
Peking University People's Hospital

zhongze fang (✉ fangzhongze@tmu.edu.cn)  
Tianjin Medical University  https://orcid.org/0000-0003-1113-9262

Research

Keywords: asparagine and aspartate homeostasis, sex, age, type 2 diabetes risk interaction

DOI: https://doi.org/10.21203/rs.3.rs-34037/v4

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background Asparagine and aspartate homeostasis link with type 2 diabetes (T2D). This study aimed to explore whether asparagine and aspartate metabolism interacted with sex and age to increase the risk of T2D.

Methods From 27 May 2015 to 3 August 2016, we consecutively retrieved 1032 T2D patients and 1522 subjects without T2D from a tertiary care hospital in Liaoning, China. Restricted cubic spline nested in the logistic regression was used to draw odds ratio curves of plasma asparagine to aspartate ratio for T2D by sex and age. Cutoff point was select where curves went apart, indicating possible interaction. Addictive interactions of asparagine to aspartate ratio with sex or age and secondary interaction with copresence of unfavorable sex and age were further estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S).

Results Ratio of asparagine to aspartate >1.5 was associated with elevated risk of T2D (OR: 7.99, 95%CI: 5.50 to 11.6), which was enhanced by female gender to 13.6, (95%CI: 8.10-22.9) and by >50 years of age to 28.7 (14.6-56.3), with significant additive interactions. There was a significant secondary-interaction of copresence of female sex and > 50 years of age with high asparagine to aspartate ratio for increased T2D risk with the OR being further increased to 34.4 (20.5 - 57.5).

Conclusions High asparagine to aspartate ratio was associated with markedly increased risk of T2D, which was further amplified by either female gender or >50 years of age, and especially both.

Background

There is a small but significant sex differences in the prevalence of type 2 diabetes (T2D) globally (1-3). Cross-sectional and prospective investigations all showed that males are more likely to have insulin resistance and to have higher prevalence of diabetes in late adolescence up to midlife than females (4, 5). Females experienced a sharply increased risk of diabetes after the menopause, resulting in nearly equal prevalence of T2D as males in older life (1, 2, 6). The related pathophysiology include but is not limited to gene, diet, physical activity and sex hormone fluctuance (7-9). Despite of extensive research on this issue, the underlying mechanisms remain elusive(1). Nevertheless, unraveling sex-specific mechanisms on T2D onset, especially in different life span, is of importance for personalized diabetes management. With advances in metabolomics research and techniques, metabolite profiling has the potential to identify pathways associated with metabolic risk and to provide novel insight into this scientific issue.

Asparagine and aspartate can be converted to each other by corresponding enzymes with metabolism fluctuation. Asparagine synthetase expresses in many tissues especially pancreas and catalyzes the conversion of aspartate to asparagine in an ATP-dependent way (10, 11); asparaginase can catalyze the conversion of asparagine to aspartate (12). As a critical source of energy, building blocks of protein synthesis and signaling molecules, asparagine and aspartate were found to be linked to metabolic disorder traits and metabolic pathways in animal and human studies: knockdown of asparagine synthetase in rat liver reduced plasma glucose (13); adenosine monophosphate activated protein kinase (AMPK) α phosphorylation and the mammalian target of rapamycin complex 1 (mTORC1), two key pathways participating in metabolism, were sensitive to asparagine concentration (14, 15). In this connection, Framingham Heart Study showed that
asparagine was inversely associated with fasting insulin while aspartate was inversely associated with fasting glucose (16); overweight/obese pregnant women had a higher total amount of asparagine and aspartate (17). Interestingly, these traits and pathways were previously found to be associated with crucial mechanisms which contributed to sex difference in different age groups, for example, higher insulin resistance in males than females before older life (5) and sudden deficiency of estrogens due to menopause at ~ 50 years of age in females (18-20). Hence, it was possible that asparagine and aspartate homeostasis might help interpret these sex-specific mechanisms.

Based on the above observations, we hypothesize that asparagine and aspartate homeostasis is linked to the sex difference in the prevalence of diabetes. Therefore, this hospital-based study aimed to examine additive interactions of high ratio of asparagine and aspartate with female gender and >50 years of age on the risk of T2D.

**Methods**

**Research design and study patients**

The study patients and methods were described previously (21). From 27 May 2015 to 3 August 2016, a total of 71,020 patients were hospitalized in Liaoning Medical University First Affiliated Hospital (LMUFAH). Among them, 1032 consecutive patients were diagnosed with T2D and had complete information on height, weight, blood pressure. Non-T2D subjects were recruited from hospital’s physical examination center where individuals had regular health examination. 1522 of them had metabolomic profiles measured and were included in this analysis. All subjects were over 18 years old. T2D was diagnosed according to the 1999 World Health Organization’s criteria or use of antidiabetic drugs (22). The Ethics Committee for Clinical Research of LMUFAH approved the ethics of the study, and informed consent was waived by the above ethics committee due to the retrospective nature of the study, which is consistent with the Declaration of Helsinki.

**Data collection and definitions**

Clinical information including demography, anthropometry, laboratory parameters, medications and disease status was extracted from electronic medical system (EMS) retrospectively. Age was calculated automatically by EMS as difference between admission year and birth year. Body mass index (BMI) was calculated as weight in kilograms divided by squared height in meters. According to the recommended Chinese criteria (23), BMI was categorized into four classes: underweight (< 18.5 kg/m²), normal weight (18.5 to 24 kg/m²), overweight (> 24 kg/m²) and obesity (≥ 28 kg/m²). Systolic blood pressure (SBP) over 140 mmHg, high-density lipoprotein cholesterol (HDL-C) less than 1 mmol/L in men and 1.3 mmol/L in women, triglyceride over 1.7 mmol/L, low-density lipoprotein cholesterol (LDL-C) over 2.6 mmol/L were defined as abnormal (24). Use of oral antidiabetic drugs and insulin, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and other antihypertensive drugs, statins and other lipid lowering drugs in hospital was documented. Complications were extracted from the electronical database, including coronary artery disease, stroke, diabetic retinopathy and diabetic nephropathy.

**Measurements of serum asparagine and aspartate**
Details of the amino acid assessment method were published previously (25). 8-h fasting blood was taken and stored as dried blood spot. 8-h fasting blood was mostly collected in the morning. As no reliable evidence has suggested circadian rhythm in conversion of asparagine to aspartate, time of sampling was unlikely to affect the levels of amino acids. Amino acids quality control (QC) standards used in our study were provided by Chromsystems (Grafelfing, Germany). LC-MS/MS analysis was performed with AB Sciex 4000 QTrap system (AB Sciex, Framingham, MA, USA). Analyst v1.6.0 software (AB Sciex) was used for system control and data collection. ChemoView 2.0.2 (AB Sciex) was used for data preprocessing.

**Statistical analysis**

We first compared difference of clinical and biochemical characteristics of participants between T2D and non-T2D. For continuous variables, Q-Q plot was used to checked normality. Data with normal distribution was expressed as means (standard deviations) while data with skewed distribution was expressed as medians (interquartile ranges). Non-paired Student’s t-test (or Mann-Whitney U test when appropriate) was used to measure the difference; for categorical variables, data was presented as frequencies (percentage) and Chi-square test (or fisher test if appropriate) was used for difference comparison.

Age was stratified into a binary variable at 50 years, and >50 years of age in female roughly represented the postmenopausal period. Restricted cubic spline (RCS) nested in the logistic regression was also performed to examine the full-range associations between age with T2D risk and to ascertain the selected cutoff point at 50 years of age (26). The associations between asparagine or aspartate alone with T2D were examined with RCS too. Next, to visualize potential interaction between asparagine to aspartate ratio with sex or age, we also performed RCS to examine the full-range associations between asparagine to aspartate ratio with T2D in different sex and age groups which derived from cutoff points chosen above. That OR curves turned apart and became unparallel may imply an additive interaction. The point of asparagine to aspartate ratio where curves turned apart and unparallel was selected as the cutoff point to categorize the ratio for further analysis.

Then, we formally tested the additive interaction by calculating relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) (27). RERI > 0, AP > 0, or S > 1 indicates biological interaction. First, we used univariable and multivariable logistic regression models to obtain odds ratio (OR) and 95% confidence (CI) of asparagine, aspartate, asparagine to aspartate ratio, sex and age (all as categorical variables) for T2D. Asparagine to aspartate ratio (>1.5 and ≤ 1.5 μmol/L, sex (< 50 and ≥ 50 years, BMI (<18.5, 18.5~24.0, 24.0~28.0 and ≥28.0 kg/m²), SBP (<140 and ≥ 140 mmHg), LDL-C (<2.60 and ≥ 2.60 mmol/L), HDL-C (<1.00 mmol/L in male or <1.30 mmol/L in female as low level and ≥1.00 in male or ≥1.30 in female as high level) and triglyceride (<1.70 mmol/L and ≥1.70 mmol/L) were included in multivariable analysis. Through steps above, high asparagine, low aspartate, high asparagine to aspartate ratio, female and age over 50 years old were identified as risk factors of T2D (see Table 2); second, to estimate the biological interaction between asparagine to aspartate ratio and age or sex, we created four variables (see Table 2): 1) asparagine to aspartate ratio ≤ 1.5 μmol/L and age <50 years (or male) (as reference); 2) asparagine to aspartate ratio ≤ 1.5 μmol/L and age ≥ 50 years (or female); 3) asparagine to aspartate ratio > 1.5 μmol/L and age < 50 years (or male); 4) asparagine to aspartate ratio > 1.5 μmol/L and age ≥ 50 years (or female). Confounders listed above were also adjusted in multivariable additive models.
We further tested the second-order interaction between high asparagine to aspartate ratio and coexistence of female sex and >50 years of age. The four variables were created as combination of copresence of female sex and >50 years of age and high asparagine to aspartate ratio: 1) female and >50 years of age =no plus low asparagine to aspartate ratio (use as reference); 2) female and >50 years of age =yes plus low asparagine to aspartate ratio; 3) female and >50 years of age =no plus high asparagine to aspartate ratio; 4) female and >50 years of age =yes plus high asparagine to aspartate ratio (see Table 3). Likewise, RERI, AP and S were used to measure biological interactions.

To exclude potential influence of diabetes-related parameters on association between asparagine to aspartate ratio and T2D, especially in the context of gender, we included patients without diabetes complications or use of anti-diabetic medications in the analysis and repeated logistic regression and additive interaction analysis; to avoid some possible bias from different age distribution for each gender or different gender distribution for each age groups, we also compared male and female gender in different age groups, as well as age over and below 50 years old in each gender.

Partial Pearson correlation (data with normal distribution) or Spearman correlation (data with skewed distribution) analysis was used to test correlations between asparagine to aspartate ratio and available diabetes traits, i.e., BMI, SBP, triglyceride, LDL-C, HDL-C, HbA1c and duration of diabetes while adjusted for age and sex.

All analysis was performed using SAS version 9.4 (SAS institute Inc., Cary, NC, USA) and R version 3.6.0. P values of < 0.05 were considered statistically significant.

Results

Characteristics of the study population

There were 1032 T2D and 1522 non-T2D subjects. The mean age of patients with T2D was 57.2 (SD: 13.8) years and the mean age of subjects without was 46.4 (13.7) years. Of them, 53.2% of T2D and 74.3% of non-T2D were males. Patients with T2D had a mean HbA1c of 9.60% (SD, 2.38%). Duration of diabetes was 5 (IQR: 0-10) years. Patients with T2D were older and had higher SBP, triglyceride, tyrosine, asparagine and asparagine to aspartate ratio than subjects without T2D. Levels of HDL-C, LDL-C and aspartate were lower in T2D than in non-T2D. BMI was similar between T2D and non-T2D. The prevalence of diabetes complications and drug use were shown in Table 1. (Table 1)

Addictive interaction of asparagine to aspartate ratio with age and sex for T2D

Age was associated with T2D in a J-shape relationship (Figure 1). The risk of T2D rapidly increased from 50 years upwards. OR (95%CI) of age ≥ 50 vs. < 50 years was 3.96 (2.99-5.24) in multivariable analysis (Table 2); Asparagine was positively while aspartate was inversely associated with increased T2D risk non-linearly (figure S1). Exposure to high asparagine or low aspartate led to 2.38-fold (95%CI, 1.77-3.21) and 6.33-fold (4.54-8.82) risk of diabetes compared to their counterparts, respectively (table 2); Asparagine to aspartate ratio was associated with increased risk of T2D and at 1.5 upwards, the two curves in patients aged ≥50 years and < 50 years went apart (figure 2A) and became unparallel in both males and females (figure 2B). OR (95%CI) of high
vs. low asparagine to aspartate ratio for T2D was 7.00 (5.27-9.30) in univariable analysis and 7.99 (5.50-11.6) in multivariable analysis. Female had 1.82-fold risk of male counterparts (Table 2).

Using low asparagine to aspartate ratio and < 50 years of age as the reference, the OR was 3.43 (95% CI: 1.61-7.29) for individuals who were ≥50 years of age and had a low asparagine to aspartate ratio; and 7.10 (95% CI: 3.60-14.0) for individuals who were <50 years of age and had a high asparagine to aspartate ratio, after adjusting for confounders. Coexistence of older age and high asparagine to aspartate ratio sharply increased the effect size to 28.7 (95%CI: 14.6-56.3), with significant additive interaction (RERI: 19.2, 95%CI: 6.02-32.3; AR: 0.67, 0.57-0.77; S: 3.25, 2.32-4.55). (Table 2)

Similarly, using low asparagine to aspartate ratio and male as the reference and in multivariable analysis, the OR was 1.49 (95% CI: 0.76-2.93) in patients who were female and had a low asparagine to aspartate ratio; and 7.19 (95% CI: 4.41-11.7) in patients who were male and had a high asparagine to aspartate ratio. Being female and having a high asparagine to aspartate ratio had the highest OR, i.e., 13.6 (95% CI: 8.10-22.9). The additive interaction was significant (RERI: 5.95, 95%CI: 1.60-10.3; AR: 0.44, 0.26-0.62; S: 1.89, 1.32-2.71) (Table 2).

**Second-order interaction of high asparagine to aspartate ratio and coexistence of female sex and older than 50 years old**

There was a significant second-order additive interaction between high asparagine to aspartate ratio and coexistence of female gender and ≥50 years of age for risk of T2D (Table 3). Coexistence of female gender and ≥50 years of age greatly amplified the OR for T2D from 7.99 (5.50-11.6) to 34.4 (20.5-57.5). The additive interaction was highly significant (RERI: 26.1, 95% CI 11.0-41.2; AP: 0.76, 0.66-0.86; and S:4.58, 95% CI: 2.96-7.08) in multivariable analysis.

**Sensitive analysis**

Excluding patients with diabetes complications or under anti-diabetic medications only slightly changed effects of asparagine to aspartate ratio on diabetes. The additive interaction of asparagine to aspartate ratio and sex on T2D was significant (table S1).

Females increased T2D risk only in group with ≥50 years of age (OR, 2.35; 95%CI, 1.69-3.28); in male gender, OR (95%CI) of age ≥ 50 vs. < 50 years was 2.64 (1.92-3.62). In female gender, OR (95%CI) of age ≥ 50 vs. < 50 years was 6.65 (3.95-11.2) (table S2).

**Correlations of asparagine to aspartate ratio with available diabetes traits**

Asparagine to aspartate ratio was positively correlated with BMI, SBP, triglyceride, HbA1c (correlation coefficients ranged from 0.07 to 0.15, all P values<0.05) and inversely correlated with HDL-C (correlation coefficients: -0.27, P<.0001); Correlations of asparagine to aspartate ratio with LDL-C and duration of diabetes were not statistically significant. (table S3)

**Discussion**
In present study, we found that high asparagine to aspartate ratio, i.e., $\geq 1.5$, was associated with elevated risk of T2D, and its effect size was greatly enhanced by female gender and $>50$ years of age, especially by copresence of both. Our findings showed that abnormal asparagine and aspartate homeostasis contributed to an increased risk of T2D and the abnormal asparagine and aspartate homeostasis had a female gender and older age specific effect on the risk of T2D in Chinese adults.

Only a few studies reported inconclusive findings regarding the associations of asparagine and aspartate with the risk of T2D. In subjects without diabetes and cardiovascular diseases, asparagine was inversely correlated with fasting insulin and insulin resistance while aspartate was inversely correlated with plasma glucose (16); Two prospective observational studies in the United States found that baseline plasma asparagine was a protective marker of diabetes (28, 29). In these researches, findings about aspartate were accordant with ours, but results about asparagine were opposite to ours. The discrepancy may derive from stage of sampling: asparagine is important precursor for many other amino acids and thus has abundant functions. Imbalanced nutrition consumption or endoplasmic reticulum stress, which are risk factors for diabetes, can accelerate asparagine consumption and activate asparagine synthetase gene (ASNS) subsequently (30). Potential explanation for this is that before the onset of diabetes, asparagine is likely depleted whereas ASNS remains the same; then in later period, persistent adverse stimulation may upregulate ASNS and result in asparagine overload and aspartate deficiency. Notably, in our study, patients with longer duration of diabetes did not have higher asparagine to aspartate ratio compared with patients with shorter duration of diabetes. We speculated that upregulate ASNS may accelerate process of hospitalization. So it is reasonable that patients with different duration of diabetes have the same asparagine to aspartate ratio level. In this regard, information about individual differences in gene expression will be valuable. We cannot exclude asparaginase downregulation although limited researches investigated impact of environment on asparaginase. Given that asparaginase can be produced by Escherichia coli, our study may provide clues linking gut microbiota and diabetes (12).

Asparagine can also suppress phosphorylation of AMPK and upregulate mTORC1 (15, 31), which can lead to increased insulin resistance and reduced $\beta$ cell reserve (32). Our study also indicates that low aspartate could lead to T2D, nevertheless the mechanistic studies are lacking to explain this association. In the current study, we further found that abnormal asparagine and aspartate homeostasis had a gender and age specific effect on the risk of T2D and female gender and older age (defined as over 50 years of age), particularly, copresence of female and older age, greatly amplified the effect of abnormal asparagine and aspartate homeostasis on the risk of T2D. Abnormal asparagine and aspartate homeostasis explained some of elevated risk in females aged greater than 50 years. One acknowledged assumption of higher risk of T2D for females at later adult life was hormonal transition of menopause, i.e., estrogen depletion (6, 18). Previous, estrogen was known as an important regulator of metabolic status (33). Obesity was accelerated in individuals with lower levels of estrogen. Estrogen deficiency can also induce insulin resistance, decreasing insulin releasing and $\beta$-cell apoptosis (18). In this connection, randomized controlled trials showed that menopausal hormone therapy delayed the onset of T2D in women (34). Our results further supports that hormonal transition at postmenopausal period may play a role in the different effect of asparagine and aspartate homeostasis for the risk of T2D. It is of interest to examine evidence about interactions of asparagine and aspartate homeostasis with estrogen for T2D. Estrogen exposure upregulated AMPK activity in skeletal muscle of ovariectomized mice (35). When culturing myotubes and adipocytes with and without estrogen, estrogen activated AMPK and suppressed mTORC1 subsequently dependent on nutrient availability (36). So it was plausible that at some
condition, e.g., nutrition unavailability, estrogen deficiency suppressed AMPK and upregulated mTORC1, which is consistent with the observed effects of asparagine supplement for T2D (14, 15). Therefore, we speculate that coexistence of abnormal asparagine and aspartate homeostasis and estrogen deficiency accelerate the progress of insulin resistance and promoted onset of T2D via AMPK- mTORC1 pathway. In other words, estrogen deficiency influences metabolism based on asparagine and aspartate homeostasis. Nevertheless, we couldn't exclude other mechanisms given to the complex function of estrogen and limited knowledge of mechanisms in relation to abnormal asparagine and aspartate homeostasis and metabolic disorders. Some studies found that mechanism of estrogen on glucose homeostasis may independent of insulin action (37), so maybe amino acids metabolism can provide some clues for this.

Our study had important implications for both clinic and basic science. The incidence of T2D differs between males and females, but the reasons for this disparity remain elusive. Our study helps understand why females after menopause had increased risk of metabolic disease including T2D. Postmenopausal females with high asparagine to aspartate ratio had higher risk of T2D, which deserves more attention. Future physiological investigations into this mechanism are warranted to better understand the molecular mechanism and find possible ways to reduce disease burden of T2D in this high risk group. Our study had several limitations. First, our study was a retrospective cross-sectional survey, thus the causal relationship cannot be established and prospective cohorts are needed to confirm the findings of our study. Second, our subjects were in-patients with relatively severe condition. Our findings may not be generalizable to the general populations. Third, there were more proportion of males than females, so there might be some selective bias in our study. Prospective studies are thus warranted. Fourth, we didn't measure estrogen in our patients, so we could not examine associations of amino acids and estrogen. Fifth, although most women experience menopause at around 50 years old, we did not collect the accurate age of menopause. So we cannot know the distribution of pre- and post-menopaused individual in our cohort. Indeed, whether women that underwent menopause earlier in life have increased asparagine to aspartate ratio is of significance and remains to be determined.

In conclusion, we found that high asparagine to aspartate ratio was associated with elevated risk of T2D. The effect of high asparagine and aspartate ratio was greatly enhanced by female gender and being greater than 50 years of age, especially by copresence of both. Our findings suggest that abnormal asparagine and aspartate homeostasis at postmenopausal period may be one of the reasons for the increased risk of T2D in the high T2D-risk group. Further investigations into the underlying molecular mechanisms are warranted for better understanding of the cause of T2D and possible prevention of T2D in the high risk group.

Perspectives and significance

Sex difference exists along life span although specific mechanism and consequence haven't been figured out. However, plenty of previous studies implied possible relationships between biological sex and metabolic disease including T2D. Our study provided additional clues about why females after menopause had increased risk of metabolic disease including T2D, which was meaningful for personalize management of T2D especially for postmenopausal women. In the future, prospective studies were warranted to replicate our findings and more mechanistic investigations are needed to elucidate the molecular mechanisms for identification of more efficient and personalized therapeutic targets for males and females in different life course.
Declarations

Acknowledgement

The authors thank all the physicians and doctors in the Liaoning Medical University First Affiliated Hospital who participated in the study and extended their support for data collection. The authors also thank all the laboratory technicians in Dalian Institute of Chemical Physics for measuring the metabolites.

Contribution statements

Z-ZF designed the study. R-QH had gave critical comments related to additional analysis and paper editing in the process of revision. H-HL analyzed the data and wrote the first draft. XY revised and gave critical comments on the first draft. X-FF collect the information and contributed to the writing of this manuscript.

Declaration of interests

The authors declared no conflict of interest.

Funding

This work was supported by the project for the National Key Research and Development Program of China (2019YFA0802302, 2019YFA0802300), State Key Project on Infectious Diseases of China (2018ZX10723204).

Ethics approval and consent to participate

The Ethics Committee for Clinical Research of LMUFAH approved the ethics of the study

Consent for publication

Informed consent was waivered by the above ethics committee due to the retrospective nature of the study.

Availability of data and materials

Data are available on request to the corresponding author.

References

1. Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62(10):1761-72.

2. Li J, Ni J, Wu Y, et al. Sex Differences in the Prevalence, Awareness, Treatment, and Control of Diabetes Mellitus Among Adults Aged 45 Years and Older in Rural Areas of Northern China: A Cross-Sectional, Population-Based Study. Frontiers in endocrinology. 2019;10:147.

3. Choi YJ, Kim HC, Kim HM, et al. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes care. 2009;32(11):2016-20.

4. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet.369(9563):0-756.
5. Jeffery SC, Hosking J, Jeffery AN, et al. Insulin resistance is higher in prepubertal girls but switches to become higher in boys at age 16: A Cohort Study (EarlyBird 57). Pediatric diabetes. 2018;19(2):223-30.

6. Gurka MJ, Vishnu A, Santen RJ, et al. Progression of Metabolic Syndrome Severity During the Menopausal Transition. Journal of the American Heart Association. 2016;5(8).

7. Sattar N. Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best practice & research Clinical endocrinology & metabolism. 2013;27(4):501-7.

8. Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia. 2011;54(12):3003-6.

9. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of internal medicine. 2014;161(4):249-60.

10. Richards NGJ, Kilberg MS. Asparagine Synthetase Chemotherapy. Annual Review of Biochemistry. 2006;75(1):629.

11. Milman HA, Cooney DA. The distribution of l-asparagine synthetase in the principal organs of several mammalian and avian species. Biochemical Journal. 1974;142(1):27-35.

12. Zuo S, Zhang T, Jiang B, et al. Recent research progress on microbial L-asparaginases. Applied microbiology and biotechnology. 2015;99(3):1069-79.

13. Iida S, Kamiya H, Nakaya A, et al. Reduced plasma glucose by asparagine synthetase knockdown in the mouse liver. Biological & pharmaceutical bulletin. 2013;36(12):2009-11.

14. Wang X, Liu Y, Wang S, et al. Asparagine reduces the mRNA expression of muscle atrophy markers via regulating protein kinase B (Akt), AMP-activated protein kinase alpha, toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling in weaning piglets after lipopolysaccharide challenge. The British journal of nutrition. 2016;116(7):1188-98.

15. Krall AS, Xu S, Graeber TG, et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature communications. 2016;7:11457.

16. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222-31.

17. Jacob S, Nodzenski M, Reisetter AC, et al. Targeted Metabolomics Demonstrates Distinct and Overlapping Maternal Metabolites Associated With BMI, Glucose, and Insulin Sensitivity During Pregnancy Across Four Ancestry Groups. Diabetes care. 2017;40(7):911-9.

18. Meyer MR, Clegg DJ, Prossnitz ER, et al. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta physiologica (Oxford, England). 2011;203(1):259-69.

19. Alonso C, Fernandez-Ramos D, Varela-Rey M, et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology. 2017;152(6):1449-61.e7.

20. Alayev A, Salamon RS, Berger SM, et al. mTORC1 directly phosphorlrates and activates ERAlpha upon estrogen stimulation. Oncogene. 2016;35(27):3535-43.

21. Li J, Cao YF, Sun XY, et al. Plasma tyrosine and its interaction with low high-density lipoprotein cholesterol and the risk of type 2 diabetes mellitus in Chinese. J Diabetes Investig. 2019;10(2):491-8.

22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic
medicine: a journal of the British Diabetic Association. 1998;15(7):539-53.

23. Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomedical and environmental sciences: BES. 2004;17 Suppl:1-36.

24. Lam DW, LeRoith D. Metabolic Syndrome. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

25. Wang Q, Sun T, Cao Y, et al. A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. OncoTargets and therapy. 2016;9:1389-98.

26. May M. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Frank E Harrell Jr, New York: Springer 2001, pp. 568, $79.95. ISBN 0-387-95232-2. International Journal of Epidemiology. 2002;31(3).

27. Andersson T, Alfredsson L, Källberg H, et al. Calculating Measures of Biological Interaction. European Journal of Epidemiology. 20(7):575-9.

28. Rebholz CM, Yu B, Zheng Z, et al. Serum metabolomic profile of incident diabetes. Diabetologia. 2018;61(5):1046-54.

29. Otosson F, Smith E, Melander O, et al. Altered Asparagine and Glutamate Homeostasis Precede Coronary Artery Disease and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2018;103(8):3060-9.

30. Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. American journal of physiology Endocrinology and metabolism. 2013;304(8):E789-99.

31. Wang X, Liu Y, Wang S, et al. Asparagine reduces the mRNA expression of muscle atrophy markers via regulating protein kinase B (Akt), AMP-activated protein kinase α, toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling in weaning piglets after lipopolysaccharide challenge. British Journal of Nutrition. 2016;116(7):1188-98.

32. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-76.

33. Brown LM, Clegg DJ. Central effects of estradiol in the regulation of food intake, body weight, and adiposity. The Journal of steroid biochemistry and molecular biology. 2010;122(1-3):65-73.

34. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Jama. 2013;310(13):1353-68.

35. D’Eon TM, Souza SC, Aronovitz M, et al. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. The Journal of biological chemistry. 2005;280(43):35983-91.

36. Cederroth CR, Vinciguerra M, Gjinovci A, et al. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes. 2008;57(5):1176-85.

37. Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine reviews. 2017;38(3):173-88.

Tables
Table 1. Clinical and biochemical characteristics of participants according to T2D

| Characteristics                      | Non-T2D | T2D     | P-value  |
|--------------------------------------|---------|---------|----------|
| No. of subjects                      | 1522    | 1032    |          |
| Duration of diabetes, years          | 5 (0-10)| 57.2±13.8 | <.0001  |
| Age, years                           | 46.4±13.7 | 57.2±13.8 | <.0001  |
| ≥50 years old                        | 640 (42.1) | 785 (76.1) | <.0001  |
| Male sex                             | 1131 (74.3) | 549 (53.2) | <.0001  |
| BMI, kg/m²                           | 25.4±3.5 | 25.3±3.9 | 0.3338  |
| BMI < 18.5                           | 23 (1.5) | 27 (2.6) | 0.2012  |
| BMI ≥18.5 and <24                    | 504 (33.1) | 354 (34.3) |         |
| BMI ≥24 and <28                      | 653 (42.9) | 430 (41.7) |         |
| BMI ≥ 28                             | 342 (22.5) | 221 (21.4) |         |
| SBP, mmHg                            | 130.9±17.2 | 140.4±24.0 | <.0001  |
| HDL-C, mmol/L                        | 1.55±0.35 | 1.08±0.35 | <.0001  |
| <1.00 in male or <1.30 in female     | 123 (8.1) | 785 (76.1) | <.0001  |
| LDL-C, mmol/L                        | 3.06±0.70 | 2.89±1.01 | <.0001  |
| LDL-C >2.60 mmol/L                   | 1127 (74.1) | 434 (42.1) | <.0001  |
| Triglyceride, mmol/L                 | 1.51 (1.02-2.35) | 1.67 (1.11-2.38) | 0.0126  |
| Triglyceride >1.70                   | 644 (42.8) | 361 (48.5) | 0.0097  |
| HbA1c, %                             | 9.60 (2.38) | 6 (1.98-89.50) | <.0001  |
| Asparagine, μmol/L                   | 70.68 (59.77-84.12) | 74.85 (61.98-89.50) | <.0001  |
| >88, μmol/L                          | 303 (19.9) | 280 (27.1) | <.0001  |
| Aspartate, μmol/L                    | 42.54 (29.67-58.01) | 28.37 (20.91-37.56) | <.0001  |
| <65, μmol/L                          | 1275 (83.8) | 1014 (98.3) | <.0001  |
| Asparagine: aspartate                | 1.72 (1.26-2.37) | 2.60 (1.99-3.55) | <.0001  |
| ≤1.5 μmol/L                          | 578 (38.0) | 87 (8.4) | <.0001  |
| >1.5 μmol/L                          | 944 (62.0) | 945 (91.6) |         |
| Macrovascular complications           |         |         |          |
| Prior CAD                            | 210 (20.4) |         |          |
| Prior stroke                         | 199 (19.3) |         |          |
| Microvascular complications           |         |         |          |
| Diabetic retinopathy                 | 162 (15.7) |         |          |
| Diabetic nephropathy                 | 187 (18.1) |         |          |
| Diabetes medications                 |         |         |          |
| Oral antidiabetic drugs              | 564 (55.1) |         |          |
| Insulin                              | 770 (74.8) |         |          |
| Statins                              | 369 (35.9) |         |          |
| Other lipid-lowering drugs           | 23 (2.2) |         |          |
| ACEIs                                | 135 (13.1) |         |          |
| ARBs                                 | 134 (13.0) |         |          |
| Other antihypertensive drugs         | 309 (29.9) |         |          |
Abbreviations: T2D, type 2 diabetes; BMI, body mass index; SBP, Systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; CAD, coronary artery disease; ACEI, Angiotensin - converting enzyme inhibitors; ARB, Angiotensin receptor blockers.

Data are means ± standard deviation (SD) or median (interquartile range [IQR]) or n (%).
P values were derived from independent-samples Student t test for normally distributed variables, Mann-Whitney U test for skewed distributions, Chi-square test (or fisher test if appropriate) for categorical variables.

Table 2. Interactive effects of asparagine and aspartate homeostasis with sex and age for T2D risk

| Univariable model | | | Multivariable model | | |
|-------------------|------------------|------------------|------------------|------------------|
| | | | | |
| Asn > 88 vs. ≤ 88, μmol/L | 1.69 (1.38-2.08) | <0.0001 | 2.38 (1.77-3.21) | <0.0001 |
| Asp < 65 vs. ≥ 65, μmol/L | 11.7 (6.49-21.0) | <0.0001 | 6.33 (4.54-8.82) | <0.0001 |
| Asn: Asp >1.5 vs. ≤ 1.5 | 7.00 (5.27-9.30) | <0.0001 | 7.99 (5.50-11.6) | <0.0001 |
| Age ≥ 50 vs. < 50 years old | 4.62 (3.79-5.64) | <0.0001 | 3.96 (2.99-5.24) | <0.0001 |
| Female vs. male | 2.55 (2.12-3.06) | <0.0001 | 1.82 (1.38-2.42) | <0.0001 |

Additive interaction model of asparagine to aspartate ratio and age

| | | |
| Asn: Asp ≤1.5 & age < 50 years old | Reference | Reference |
| Asn: Asp ≤1.5 & age ≥ 50 years old | 4.99 (2.60-9.60) | <0.0001 | 3.43 (1.61-7.29) | 0.0014 |
| Asn: Asp >1.5 & age < 50 years old | 7.60 (4.16-13.9) | <0.0001 | 7.10 (3.60-14.0) | <0.0001 |
| Asn: Asp >1.5 & age ≥ 50 years old | 37.0 (20.5-66.9) | <0.0001 | 28.7 (14.6-56.3) | <0.0001 |

Interaction measure | Estimates | Estimates |
| RERI | 25.4 (10.4-40.5) | 19.2 (6.02-32.3) |
| AP | 0.69 (0.62-0.76) | 0.67 (0.57-0.77) |
| S | 3.40 (2.64-4.39) | 3.25 (2.32-4.55) |

Additive interaction model of asparagine to aspartate ratio and sex

| | | |
| Asn: Asp ≤1.5 & male | Reference | Reference |
| Asn: Asp ≤1.5 & female | 2.09 (1.22-3.56) | 0.0070 | 1.49 (0.76-2.93) | 0.2676 |
| Asn: Asp >1.5 & male | 6.46 (4.34-9.62) | <.0001 | 7.19 (4.41-11.7) | <.0001 |
| Asn: Asp >1.5 & female | 21.2 (14.0-32.2) | <.0001 | 13.6 (8.10-22.9) | <.0001 |

Interaction measure | Estimates | Estimates |
| RERI | 13.7 (7.48-19.9) | 5.95 (1.60-10.3) |
| AP | 0.64 (0.56-0.73) | 0.44 (0.26-0.62) |
| S | 3.09 (2.35-4.05) | 1.89 (1.32-2.71) |

Abbreviations: T2D, type 2 diabetes; Asn, asparagine; Asp, aspartate; OR, odds ratio; CI, confidence interval; RERI, risk interaction; AP, attributable proportion due to interaction; S, synergy index;

Multivariable analysis adjusted for body mass index (<18.5, 18.5~24.0, 24.0~28.0 and ≥28.0 kg/m2), systolic blood pressure (<140 and ≥140 mmHg), low-density lipoprotein cholesterol (<2.60 and ≥2.60 mmol/L), high-density lipoprotein cholesterol (<1.00 mmol/L in male or <1.30 mmol/L in female as low level and ≥1.00 in male or ≥1.30 in female as high level), triglyceride (<1.70 mmol/L and ≥1.70 mmol/L) and sex in a or age (<50 and ≥50 years old) in b;

Significant relative excess risk due to interaction (RERI) >0, attributable proportion due to interaction (AP) >0 or synergy index (S) >1 indicates a significant additive interaction.

Table 3. Secondary interaction of age and sex with asparagine and aspartate homeostasis for T2D
| Univariable additive interaction model | OR (95% CI) | P-value |
|---------------------------------------|-------------|---------|
| Female and > 50 years of age = no plus Asn: Asp ≤ 1.5 | reference |         |
| Female and > 50 years of age = yes plus Asn: Asp ≤ 1.5 | 4.53 (2.57-7.98) | <.0001 |
| Female and > 50 years of age = no plus Asn: Asp > 1.5 | 6.76 (4.70-9.71) | <.0001 |
| Female and > 50 years of age = yes plus Asn: Asp > 1.5 | 52.9 (34.4-81.2) | <.0001 |

Interaction measures

| RERI | 42.6 (22.7-62.5) |
| AP  | 0.81 (0.74-0.87) |
| S   | 5.58 (3.90-8.00) |

| Multivariable additive interaction model | OR (95% CI) | P-value |
|---------------------------------------|-------------|---------|
| Female and > 50 years of age = no plus Asn: Asp ≤ 1.5 | reference |         |
| Female and > 50 years of age = yes plus Asn: Asp ≤ 1.5 | 2.78 (1.35-5.71) | 0.0053 |
| Female and > 50 years of age = no plus Asn: Asp > 1.5 | 6.50 (4.24-9.95) | <.0001 |
| Female and > 50 years of age = yes plus Asn: Asp > 1.5 | 34.4 (20.5-57.5) | <.0001 |

Interaction measures

| RERI | 26.1 (11.0-41.2) |
| AP  | 0.76 (0.66-0.86) |
| S   | 4.58 (2.96-7.08) |

Abbreviations: T2D, type 2 diabetes; OR, odds ratio; CI, confidence interval; RERI, risk due to interaction; AP, attributable proportion due to interaction; S, synergy index.

Multivariable analysis adjusted for body mass index (<18.5, 18.5~24.0, 24.0~28.0 and ≥28.0 kg/m2), systolic blood pressure (<140 and ≥140 mmHg), low-density lipoprotein cholesterol (<2.60 and ≥2.60 mmol/L), high-density lipoprotein cholesterol (<1.00 mmol/L in male or <1.30 mmol/L in female as low level and ≥1.00 in male or ≥1.30 in female as high level) and triglyceride (<1.70 mmol/L and ≥1.70 mmol/L); Significant relative excess risk due to interaction (RERI) > attributable proportion due to interaction (AP) >0 or synergy index (S) >1 indicates a significant additive interaction.

**Figures**
Figure 1

Odds ratio curves of age for T2D risk Abbreviations: T2D, type 2 diabetes; The black curve was derived from univariable analysis, and the blue curve derived from multivariate analysis that adjusted for body mass index (<18.5, 18.5~24.0, 24.0~28.0 and ≥28.0 kg/m2), systolic blood pressure (<140 and ≥140 mmHg), low-density lipoprotein cholesterol (<2.60 and ≥2.60 mmol/L), high-density lipoprotein cholesterol (<1.00 mmol/L in male or <1.30 mmol/L in female as low level and ≥1.00 in male or ≥1.30 in female as high level) and triglyceride (<1.70 mmol/L and ≥1.70 mmol/L); The red curve stands for the reference level (i.e., the odds ratio for type 2 diabetes mellitus was 1)
Figure 2
ORs curves of asparagine to aspartate ratio for T2D in different sex and age groups. Abbreviations: ORs, odds ratios; T2D, type 2 diabetes; Asn, asparagine; Asp, aspartate; Curves derived from multivariable analysis that adjusted for body mass index (<18.5, 18.5~24.0, 24.0~28.0 and ≥28.0 kg/m2), systolic blood pressure (<140 and ≥140 mmHg), low-density lipoprotein cholesterol (<2.60 and ≥2.60 mmol/L), high-density lipoprotein cholesterol (<1.00 mmol/L in male or <1.30 mmol/L in female as low level and ≥1.00 in male or ≥1.30 in female as high level), triglyceride (<1.70 mmol/L and ≥1.70 mmol/L) and sex in (A) and age (<50 and ≥50 years old) in (B);

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- FigureS1.jpg
- supplementarymaterial.doc